Asthma is a chronic respiratory disease that affects 339 million people worldwide and has a
considerable impact on the pediatric population. Asthma symptoms can be controlled by …

Asthma is a common chronic condition in children, where the response to treatment can be
heterogeneous within a population. Genetic variations may partly explain the inconsistent …

Aim: International collaboration is needed to enable large-scale pharmacogenomics studies
in childhood asthma. Here, we describe the design of the Pharmacogenomics in Childhood …

It is well known that drug responses differ among patients with regard to dose requirements,
efficacy, and adverse drug reactions (ADRs). The differences in drug responses are partially …

Despite the availability of several classes of asthma medications and their overall
effectiveness, a significant portion of patients fail to respond to these therapeutic agents …

Asthma is a frequent disease, mainly characterized by airway inflammation, in which drug
therapy is crucial in its management. The potential of pharmacogenomics testing in asthma …

Asthma is a complex respiratory disease considered as the most common chronic condition
in children. A large genetic contribution to asthma susceptibility is predicted by the clustering …

Aims: To investigate the effects of genetic variation on treatment response to asthma
medication in children and to identify (profiles of) SNPs that characterize response …

Asthma is one of the most common chronic diseases affecting children. Despite publicized
expert panels on asthma management and the availability of high-potency inhaled …

RESULTS: Presently, there are limited examples of gene polymorphism that can influence
response to asthma therapy. Polymorphisms that alter response to asthma therapy include …